Lily Elsner

🚨 The UK’s Life Sciences Sector Plan is now live – a bold part of the UK's Modern Industrial Strategy, setting out the UK’s long-term vision for global leadership in health innovation 🇬🇧 This plan outlines how the UK will drive international collaboration and investment in: 🧬 Advanced therapeutics and biotech 💡 Healthtech, medtech and diagnostics ⚙️ Manufacturing and supply chain resilience 🌍 Global clinical trials and regulatory alignment 📈 International investment in R&D and commercialisation It aims to: ◾ Strengthen the UK’s role as a world leader in life sciences exports and innovation ◾ Accelerate international partnerships across research, development and commercialisation ◾ Leverage the UK’s regulatory expertise, top universities and global health networks We’re already seeing this vision take shape across the region: 🇹🇷 In Türkiye, British healthtech companies are partnering with local innovators to transform diagnostics and digital health delivery. 🇺🇦 In Ukraine, the UK is supporting health system resilience and rebuilding efforts through partnerships on medtech and biotech innovation. 🇰🇬 In Kyrgyzstan, life sciences and digital health are core themes of our growing trade and innovation dialogue. 👉 The UK is open for science, open for partnership, and open for progress. Explore the full strategy here: 🔗 https://lnkd.in/db8i3wXW

67

1 Comment

I wrote a piece on oligos (check the comments for the full thing)... But of course I'll offer the cliff notes here. So what are we watching across therapeutic oligos? Oligonucleotides Have Reached Validation and Commercial Scale Approved drugs (e.g., Spinraza, Inclisiran, Amvuttra) generating billions in revenue. Proven durable pharmacology, scalable manufacturing, and especially strong traction in liver-targeted applications thanks to GalNAc delivery. Expansion into Larger Indications (Cardiometabolic & CNS) Shift beyond rare diseases into broader markets like cardiovascular and neurological disorders. Recent clinical successes, big pharma partnerships, and M&A interest is strong here. Enabling Ecosystem is the Next Bottleneck and Opportunity Delivery outside the liver, next-generation chemistries, better screening tools, and scalable manufacturing (e.g., enzymes) are now the critical drivers of future growth. The supporting infrastructure has become central to furthering the field. We're watching a few specific clinical programs and how they might compete in the market across other modalities (small molecules, antibodies). If you're curious for our views, reach out and we can see how we might help you with your planning or forecasting! #oligos #drugdevelopment #pharma

71

18 Comments

1.6M GLP-1 prescriptions and no plan on how to handle them. One in five UK adults tried to get their hands on a GLP-1 medication last year. And in April alone, 1.6 million packs of Wegovy and Mounjaro were sold. But what struck me most wasn’t the demand, it was how unprepared our systems are to handle it. Pharmacists are being asked to manage eligibility, navigate shortages, and support patient education, all while being left out of the planning conversations. And in some cases, patients are turning to unregulated sources when the system can’t keep up. We keep talking about “scaling access,” but the harder question is: what does responsible scale actually look like? Who triages requests? Who ensures continuity? Who protects against misuse? These are operational questions just as much as clinical ones. And they highlight why pharmacy needs more than supply, it needs structure. With generic #Ozempic soon arriving in Canada, we can expect a huge surge in prescriptions. It’s essential that pharmacy infrastructure evolves now to meet that demand effectively and safely.  #pharmacyconsult #primarycare #healthcareinnovation #pharmacists #pharmacy

47

7 Comments

Banafsheh Salmani is the Managing Director for the Middle East at Bioniq, a London-born global healthtech company that specializes in precision supplementation, and in this role, she has seen the evolution of the launch-phase brand into a fast-growing, credible, and trusted player in the region’s health and wellness landscape. And as more women follow Salmani's lead and take up leadership roles in the health and wellness industry, she believes that they are contributing to a true paradigm shift, which is leading companies in the domain to ask different questions and set different priorities. “For too long, women’s health has been shaped by systems that weren’t necessarily designed with us in mind,” she points out. “It’s been reactive rather than proactive, and that has had real consequences: missed diagnoses, dismissed symptoms, and unmet needs. The growing presence of women in leadership is actively changing that. We bring lived experience to the table. We highlight gaps that have long gone unnoticed. And in doing so, we’re expanding the definition of innovation in healthcare—it’s no longer just about technological advancement, but about applying that innovation with empathy, inclusivity, and precision.” Salmani was one of Inc. Arabia’s 𝐖𝐨𝐦𝐞𝐧 𝐨𝐟 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐜𝐞 𝟐𝟎𝟐𝟓, a showcase of 30 women rewriting the rules of business in the MENA region—check out our full story on her here: https://lnkd.in/dnXV56GX #WomenOfInfluence #IncArabia #business #leaders #health #healthtech #healthcare #women #entrepreneurs #startups #MiddleEast #MENA #GCC

39

4 Comments